Scribe Stock
Scribe Therapeutics is focused on the engineering, delivery, and development of next-generation CRISPR molecules to rewrite and repair the underlying cause of genetic disorders.
Sign up for SecondMarket™ to view the market and buy or sell Scribe Stock
Buy + SellScribe Funding
Sign up to gain insights into Scribe funding history, including the funding round, time period, and amount raised.
Sign Up to Unlock the Data| Date | Financing Round | Amount | Price per share* | Valuation* |
|---|---|---|---|---|
| Mar 17, 2021 | Series B | 100.00M | ||
| Jan 30, 2019 | Series A | 500.00K | ||
| Oct 01, 2018 | Series A | 205.40K | ||
| Oct 01, 2018 | Series A | 20.00M |
See Scribe Valuations + Financials
*Sample data + company shown for illustrative purposes only
Gain insights Into Scribe Stock Valuation + Share Prices
View real-time Tape D™ data on Scribe stock including most recent valuation and historical share price information.
Are you an institutional investor or employee shareholder? Sign up to the SecondMarket™ trading platform.
Get Started
Scribe Management Team
Scribe Major Investors
Learn More About Scribe Stock
Buy Scribe Stock
01Sell Scribe Stock
02Scribe Stock Price
03Scribe Stock Ticker Symbol
04Criteria to Sell Scribe Stock
05Criteria to Buy or Invest in Scribe Stock
06Scribe Stock Settlement
07Scribe IPO
08*All trademarks are the property of their respective owner(s). Unless expressly stated otherwise, companies listed on this site are not sponsoring, endorsing, or otherwise affiliated with, Nasdaq Private Market, LLC, and none of the statements on this website should be attributed to a listed company.
Sign up for SecondMarket™ to view the market and buy or sell Scribe Stock
Buy + Sell*All trademarks are the property of their respective owner(s). Unless expressly stated otherwise, companies listed on this site are not sponsoring, endorsing, or otherwise affiliated with, Nasdaq Private Market, LLC, and none of the statements on this website should be attributed to a listed company.
